Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: Results from the SEARCH database

Cancer

Volumn 110, Issue 10, 2007, Pages 2202-2209

  Hamilton, Robert J ^a,b   Aronson, William J ^c,d   Presti Jr , Joseph C ^e,f   Terris, Martha K ^g,h   Kane, Christopher J ^i,j   Amling, Christopher L ^k   Freedland, Stephen J ^a,l,m  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l DURHAM VA MEDICAL CENTER   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

African Americans; Prostate neoplasms; Prostate specific antigen; Radical prostatectomy; Tumor markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 36049051624     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23012     Document Type: Article

References (31)

1. Fontaine KR, Heo M, Allison DB. Obesity and prostate cancer screening in the USA. Public Health. 2005;119:694-698.
2. Iemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol. 2000;163:143-145.
4. Cross CK, Shultz D, Malkowicz SB, et al. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol. 2002;20:2863-2868.
5. Moul JW, Wu H, Sun L, et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery. 2002;132:213-219.
6. Nielsen ME, Han M, Mangold L, et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006;176:515-519.
7. Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670-674.
8. Sohayda CJ, Kupelian PA, Altsman KA, Klein EA. Race as an independent predictor of outcome after treatment for localized prostate cancer. J Urol. 1999;162:1331-1336.
9. Powell IJ, Dey J, Dudley A, et al. Disease-free survival difference between African Americans and whites after radical prostatectomy for local prostate cancer: a multivariable analysis. Urology. 2002;59:907-912.
10. Grossfeld GD, Latini DM, Downs T, Lubeck DP, Mehta SS, Carroll PR. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J Urol. 2002;168:2510-2515.
11. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
12. Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Characterization of biochemical recurrence after radical prostatectomy. Urol Int. 2006;77:130-134.
13. Tewari A, Horninger W, Badani KK, et al. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2005;96:29-33.
14. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294:433-439.
15. Powell IJ, Banerjee M, Bianco FJ, et al. The effect of race/ ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data. J Urol. 2004;171:1508-1512.
16. Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D. Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. J Urol. 2001;166:1328-1331; discussion 1331-1322.
17. Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;274:1599-1605.
18. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001;93:388-395.
19. Jani AB, Vaida F, Hanks G, et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001;96:363-371.
20. Latini DM, Elkin EP, Cooperberg MR, Sadetsky N, Duchane J, Carroll PR. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer. 2006;106:789-795.
21. Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol. 2003;170:990-993.
22. Powell IJ, Land SJ, Dey J, et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer. 2005;103:528-537.
23. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000;92:2009-2017.
24. Bennett CL, Price DK, Kim S, et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol. 2002;20:3599-3604.
25. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76:45-48.
26. Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev. 2002;11 (10pt 1):1041-1047.
27. Paris PL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901-905.
28. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
29. Powell IJ, Zhou J, Sun Y, et al. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy. J Urol. 2004;172 (5 pt 1):1848-1852.
30. Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005;62:243-252.
31. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet. 2006;38:652-658.